Prospective, multi-centre, randomized, open-label, two arm, parallel group, active control, comparative clinical study to evaluate efficacy and safety of R-TPR-026/ Aranesp when given subcutaneously in patients for correction of anaemia due to Chronic Kidney Disease

Trial Profile

Prospective, multi-centre, randomized, open-label, two arm, parallel group, active control, comparative clinical study to evaluate efficacy and safety of R-TPR-026/ Aranesp when given subcutaneously in patients for correction of anaemia due to Chronic Kidney Disease

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 24 Jul 2017

At a glance

  • Drugs Darbepoetin alfa (Primary)
  • Indications Anaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Reliance Life Sciences
  • Most Recent Events

    • 18 Jul 2017 Status changed from recruiting to active, no longer recruiting.
    • 14 Dec 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top